From Medscape Oncology

Coverage from the

International Waldenstrom's Macroglobulinemia Foundation (IWMF) 2021 Virtual Educational Forum

October 27 - 28, 2021; Virtual/Online

October 27 - 28, 2021 Virtual/Online

IWMF 2021 Updated NCCN Guidelines Now Include Zanubrutinib for WM The new second-generation BTK inhibitor zanubrutinib is a preferred regimen for the treatment of symptomatic Waldenstrom's macroglobulinemia.
Medscape Medical News, November 4, 2021

Conference News

IWMF 2021 Decades Spent Searching for Genes Linked to Rare Blood Cancer
Medscape Medical News, November 4, 2021
IWMF 2021 Updated NCCN Guidelines Now Include Zanubrutinib for WM
Medscape Medical News, November 4, 2021

IWMF 2021 When to Treat as Important as Which Drug to Use in WM
Medscape Medical News, October 29, 2021

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Recent News on WM

Watchful Waiting Urged for Indolent Lymphoma During COVID-1 The threshold for treatment initiation during the COVID-19 pandemic should be high for patients with indolent lymphomas, the American Society of Hematology advises.
Medscape Medical News, Aug 28, 2020
FDA Approval for Zanubrutinib in Waldenström’s Macroglobulinemia The US Food and Drug Administration has approved zanubrutinib for use in the treatment of adult patients with a rare form of non-Hodgkin lymphoma.
Medscape Medical News, Sep 02, 2021
WM: Indolent But Incurable Oncologists from Washington University in St. Louis discuss the diagnosis of rare B-cell non-Hodgkin lymphomas as well as current treatment strategies for both indolent and aggressive subtypes.
Medscape Medical News, Jan 21, 2021

Previous Coverage